Wave Life Sciences (WVE) Receivables (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Receivables came in at $888000.0 in Q2 2026, down 45.08% YoY from $1.6 million in Q2 2025, and down 30.41% on a QoQ basis from $1.3 million in Q4 2025.
Wave Life Sciences (WVE) Receivables (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 11 years of Receivables data on file, last reported at $888000.0 in Q2 2026.
- Quarterly Receivables fell 45.08% year-over-year to $888000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $888000.0 (down 45.08% YoY) and the FY2025 annual result came in at $1.3 million, down 10.27% from the prior year.
- Receivables eased to $888000.0 in Q2 2026, from $1.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $21.1 million in Q4 2023 to a low of $888000.0 in Q2 2026.
- A 4-year average of $5.6 million and a median of $1.5 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2024 — Receivables slumped 93.26% — and 2025, when it advanced 25.35%.
- Tracing WVE's Receivables over 4 years: stood at $21.1 million in 2023, then tumbled by 93.26% to $1.4 million in 2024, then slipped by 10.27% to $1.3 million in 2025, then plunged by 30.41% to $888000.0 in 2026.
- The last three Receivables figures came in at $888000.0 (Q2 2026), $1.3 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 888,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 888,000.00 |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Dec 31, 2023 | 21.09 Mn |
| Sep 30, 2023 | 7.00 Mn |
| Sep 30, 2021 | 22.50 Mn |
| Mar 31, 2021 | 30.00 Mn |
| Dec 31, 2020 | 30.00 Mn |
| Sep 30, 2020 | 30.00 Mn |
| Jun 30, 2020 | 30.00 Mn |
| Mar 31, 2020 | 30.00 Mn |
| Dec 31, 2019 | 40.00 Mn |
| Sep 30, 2019 | 70.00 Mn |
| Jun 30, 2019 | 70.00 Mn |
| Mar 31, 2019 | 70.00 Mn |
| Dec 31, 2018 | 20.00 Mn |
| Sep 30, 2018 | 70.00 Mn |